drugset / Trial / NCT04318743
A Bridging Trial to Compare the PK Profile When Glepaglutide is Administered Via Vial/Syringe Versus Autoinjector.
RandomizedCrossoverOpen-labelOther
Summary
This is an open-label, randomized, single center, 2-treatment, 3-period, 3-sequence reference-replicated, crossover trial in healthy subjects to compare the PK of glepaglutide (ZP1848) after a single SC administration by vial/syringe and by autoinjector.
Timeline
- Start
- 2020-03-04
- Primary completion
- 2021-06-10
- Completion
- 2021-06-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glepaglutide | Peptide | 10 mg | Subcutaneous |
Indications
No indication recorded.